#Israel #Cancer Immunotherapy #Compugen #Holon #AI Drug Discovery

Compugen to Engage in a Fireside Chat at H.C. Wainwright Conference

Compugen Ltd., a clinical-stage cancer immunotherapy firm known for its innovative AI-driven approaches, is set to participate in a fireside chat during the H.C. Wainwright 3rd Annual AI-Based Drug Discovery and Development Conference. This virtual conference will take place on October 8-9, 2026. The specific fireside chat is scheduled for October 8 at 9:30 AM ET, providing a platform for Compugen’s management to discuss the company's advancements and future directions in drug discovery and development.

Overview of the Conference

The H.C. Wainwright Annual AI-Based Drug Discovery Conference has become a pivotal event for biopharmaceutical innovators. This year, the conference aims to showcase leading companies and their groundbreaking work in utilizing artificial intelligence to enhance drug discovery and development processes. Compugen's participation underscores its commitment to integrating cutting-edge technology in its therapeutic solutions.

Compugen’s Vision and Pipeline

Compugen is at the forefront of cancer treatment, leveraging its proprietary platform, Unigen™, which harnesses AI to discover novel therapeutic targets. The company's pipeline features several promising candidates, including:

• - COM701: Expected to be a groundbreaking anti-PVRIG antibody, currently in a randomized clinical trial focusing on ovarian cancer treatment.
• - Rilvegostomig: A bispecific antibody designed to target PD-1/TIGIT, developed in collaboration with AstraZeneca. This candidate is being tested across various clinical trials, demonstrating Compugen's strategic partnerships in advancing cancer care.
• - GS-0321: Previously known as COM503, this high-affinity antibody targets IL-18, and is actively in Phase 1 trials.

In addition to these major projects, Compugen is pursuing a suite of early-stage research programs aimed at enhancing anti-cancer immunity, highlighting the company's dedication to innovation in immuno-oncology.

Investor Engagement and Accessibility

Compugen's chat will be accessible via a live webcast on the company's Investor Relations page, ensuring that stakeholders and interested parties can engage with the latest updates directly from the source. A replay of the presentation will be available for those unable to join the live session.

This engagement at the conference is not just an opportunity for Compugen to showcase its achievements but also an avenue to connect with fellow innovators and investors who are equally passionate about revolutionizing cancer treatment through technological advancements.

Conclusion

As the landscape of drug discovery evolves with the integration of AI, companies like Compugen are poised to take advantage of these advancements to drive therapeutic innovation. The company's participation in the H.C. Wainwright Conference serves as a testament to its proactive stance in utilizing technology to combat cancer effectively. It will be intriguing to witness how their pipeline continues to develop in the coming years, potentially transforming patient care in oncology.

For more details, the live presentation will start at 9:30 AM ET on October 8, 2026. Interested participants can visit Compugen's official website to learn more about their mission and ongoing projects.